semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Disease ≥18 years old with at least one chronic disease, defined as a condition requiring prolonged management for a minimum of 3 months living in Jordan for the past year intention to remain in Jordan for the 3-month study duration met at least one of the following taking ≥5 medications, taking ≥12 doses a day, discharged from the hospital within the past 4 weeks, exposed to significant changes in medication regimens within the past 3 months, demonstrating symptoms of potential adverse drug reactions, or demonstrating a poor therapeutic response to medication therapy. A significant change to medication regimen was defined as discontinuing a medication, starting new medications, or stepping up because of actual or potential therapy failure or guideline recommendations. A poor therapeutic response was defined as persistence of symptoms despite treatment  Patients who don't have a chronic disease Cognitive or sensory impairment that may prevent conducting the interview Pregnant patients Patients who are planning to travel within the next 3 months after the baseline visit to the clinic
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Autism Spectrum Disorder The participant's Father or mother of a child who diagnosed for the period of three years since the initial time of diagnosis Father or mother who provides care and living together with the child Father or mother has the ability to read and write Arabic, and (4) father or mother age above 20 years old The center's Center provides caring only for ASD child with age 12 years and younger Provide the following services: speech, language, occupational, physiotherapy, educational, nutrition and medical services  The participant's Father or mother whose child had other chronic or illnesses (e.g, type 1 diabetes, down syndrome, learning disabilities, fetal alcohol syndrome) Foreign father or mother of a child with ASD residents in Amman Father or mother who previously participated in the intervention research (e.g, Cognitive Behavior Therapy, Mindfulness-Based Intervention) Father or mother of a child who takes any pharmacologic management of ASD (e.g,Risperdal, Ritalin) Father or mother with more than one child diagnosed with ASD The center's Center doesn't a suitable classroom for implementing the intervention program
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Vitamin D Deficiency vitamin D suboptimal status Signed Informed consent form (ICF) Caucasian race Age between 18 and 65 years at the time of the signature of Informed consent form (ICF) Willingness to avoid a consumption of any food supplements containing Vitamin D during the study, except the ones prescribed by the study researchers, and to avoid use of solarium or other artificial UVB sources Willingness to follow all study procedures  Pregnancy or breastfeeding Known or suspected allergy to any ingredient of the tested products in Part 2 Pronounced avoidance of sunshine (eg reporting of allergy to the sun) Use of food supplements containing Vitamin D or fish oil or omega 3 fatty acids in last three months prior to Special dietary habits used by a small part of the population (veganism, low-carb high-fat (LCHF) diet, caloric restriction diet, note: vegetarians are not excluded) Diets prescribed by the medical profession Disorders of the kidneys, thyroid, digestive tract, osteoporosis and other bone diseases, skin diseases Other diseases and conditions that affect the absorption and synthesis of vitamin D Exposure to stronger sunlight in the last three months prior to engaging in a survey (travel to countries with stronger sunshine, use of solarium) The consumption of margarine or plant substitutes for milk / milk products several times a day, as these foods are most often enriched with vitamin D
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 65.0-80.0,  Healthy Elderly Volunteers Healthy elderly female subjects between 65 and 80 years of age  General Subjects who participate in regular structured exercise more than 2 hours and 30 min per week or 1hour and 15 min of vigorous exercise per week Unwilling to comply with the follow-up schedule Inability or refusal to give informed consent by the patient Subject who takes multivitamins containing vitamin B3 derivatives in a dose > 200 mg/day Participation in another investigational drug study within 1 year of treatment Laboratory Serum 25-hydroxyvitamin D < 15 ng/ml Serum phosphorus > 5 mg/dL Serum alkaline phosphatase 50% above normal limit
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Postprandial Hyperglycemia Energy Expenditure Efforts will be made to age and gender match subjects (balanced number of males and females in each group). Subjects are appropriate if they are in the age range between 18 and 60. Women who are in the reproductive age will be studied at the first half of their menstrual cycle, because estrogen is known to affect the energy expenditure. Postmenopausal women taking hormonal replacement therapy will be excluded. Subjects should have: Cr <1mg/dl for women and <1.2mg/dl for men and GFR >60 ml/min/1.73m2  Subjects with diabetes, cardiovascular, cerebrovascular, pulmonary, hepatic, renal, endocrinological (PTH), or any significant medical disease will be excluded Pregnant and lactating women Subjects on regular use of medication that affects body weight and/or having a weight loss of 3% or more in the preceding 3 months Subjects with: Cr >1mg/dl for women and >1.2mg/dl for men and GFR<60 ml/min/1.73m2
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 9.0-11.0,  Bone Health Screened to be generally healthy as determined by standard medical assessment on physical and mental health Tanner stage 2 based on breast development for girls, and pubic hair in boys. Girls will have to be premenarcheal Having obtained his/her informed consent and parents or legal guardians consent  History of serious medical conditions such as intestinal or severe metabolic diseases, disorders such as diabetes, renal, hepatic or pancreatic diseases, disorders, ulcer, hyperthyroidism, malignance, chronic malnutrition, anaemia History or on therapy with medication known to interfere with bone metabolism such as steroids, hormones, diuretics, cortisone or anti-seizure medication Taking regularly any nutritional supplements and unwilling to stop for the study
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 3.0-18.0,  Fracture Healing Vitamin D3 Deficiency of Vitamin K2 Age < 18 years Presence of low-energy fracture Vitamin D serum level <30ng/ml  Age > 18 years Lack of low-energy bone fracture Oral anticoagulants treatments, which interfere with vitamin K cycle Current supplementation with vitamin vitamins K2 or vitamin D3 Osteogenesis imperfecta and other bone diseases Vitamin D concentration > 30ng/ml
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 25.0-50.0,  Myoma;Uterus Vitamin D Deficiency Polycystic Ovary The reproductive age women (25-50 years) with at least one 10 mm or larger diameter leiomyoma detected by transvaginal ultrasound were the study group  Patients with a history of myomectomy chronic systemic disease malignancy history of adenomyosis women in menopause pregnant women vitamin D supplementation lactation abortion and pregnancy loss in the last 6 months oral contraceptive / hormonal agents in the last 3 months
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Pregnancy Related Pregnancy Anemia Iron Deficiency Anemia Pregnancy Anaemia Iron treatment before 3 months of pregnancy Informed Consent Compliant with study procedures  Iron treatment after 3 months of pregnancy
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Cancer Primary Health Care GPs in the municipality of Silkeborg can refer patients with the following to Silkeborg Regional Hospital: Men and women ≥30 years old presenting with vague and non-specific abdominal symptoms for at least 3-4 weeks  Men or women who fulfil access for the CPPs
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Angiospastic; Disorder Interventional revascularization of a coronary lesion Member or beneficiary of a social security system Informed of the study  Language barrier Minor Pregnant woman Person under guardianship Person deprived of his/her liberty Refusal to participate
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Osteoarthritis, Knee Psychological all new patient present to AHNH clinic referred for osteoarthritis for considering joint replacement Present with knee pain (unilateral or bilateral) contributed by osteoarthritis  mentally unsound dialectic speaker that difficult to communicate
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-30.0,  Surface Electromyography Muscular Fatigue Participants will be males and females between the ages of 18 years Participant has provided written and dated informed consent to participate Participant is willing and able to comply with the protocol Participant is apparently healthy and free from disease, as determined by a health history questionnaire Participant agrees to abstain from lower body exercise 3 days prior to each testing visit Participant has completed at least 1 lower body workout every week for the past 6 months  Participant reports any unusual adverse events associated with this study that in consultation with their physician recommends removal from the study Participant begins consumption of new supplement during the timeline of this study Participant is unable to refrain from consuming pre-workout supplement prior to testing sessions Participant is unwilling to refrain from lower body exercise at least 3 days prior to each testing session
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 16.0-65.0,  Osteochondral Fracture of Talus Patients with a symptomatic osteochondral lesion of the Talus Magnetic resonance of the ankle showing osteochondral injury of a single talus, with perilesional oedema  Recurrent osteochondral lesions of the talus Multiple osteochondral lesions Severe ankle instability, requiring open repair History of a previous foot or ankle surgery of the ipsilateral foot Rheumatoid arthritis Inability to return to the surgery site to practice long-term follow-up evaluations or lack of readiness to complete the indicated evaluation forms Patients with a qualitative or quantitative commitment that prevents consent or assent their participation in the study
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Atrial Fibrillation Age 18 years or above Admission with atrial fibrillation or clinic visit for atrial fibrillation Signing the consent form  Age less than 18 years Refusal of signing the censent form Grave systemic disease with high probability of in hospital death
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  X-linked Hypophosphatemia Subjects who provide written informed consent after the nature of the study has been explained, and prior to any research-related procedures. 2. Subjects who participated in Study UX023-CL303 or UX023-CL304. Any subjects that did not complete Study UX023-CL303 or UX023-CL304 may be included on a case-by-case basis. Subjects' enrolment is not dependent on any response to Primary or Secondary endpoints in studies UX023-CL303 or UX023-CL304. 3. Willing to provide access to prior medical records for the collection of historical growth, biochemical and radiographic data, and disease history. 4. Must, in the opinion of the investigator, be willing and able to complete all aspects of the study, adhere to the study visit schedule and comply with the assessments. 5. Females of child-bearing potential must have a negative urine pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not to be of child-bearing potential those who have been in menopause for at least two years prior to Screening, or have had tubal ligation at least one year prior to Screening, or have had a total hysterectomy or bilateral salpingo-oophorectomy. If sexually active, male and female subjects must be willing to use one highly effective method of contraception for the duration of the study  Hypocalcemia or hypercalcemia, defined as serum calcium levels outside the age-adjusted normal limits and deemed as clinically significant in the opinion of the investigator. 2. Presence of a concurrent disease or condition that would interfere with study participation or affect safety in the opinion of the investigator or Sponsor. 3. Use of any investigational product other than burosumab or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments. 4. Subjects with major protocol deviations in Study UX023-CL303 or UX023-CL304 which in the view of the investigator places the subject at high risk of poor treatment compliance or of not completing the study. 5. Subjects who discontinued treatment from Study UX023-CL303 or UX023-CL304 due to either a grade ≥3 treatment-related hypersensitivity reaction or a burosumab-related hypersensitivity reaction reported as a SAE
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Total Knee Arthroplasty Adults who have OA and need a total knee replacement  Patients had abnormal blood coagulation. 2. Patients were diagnosed as rheumatoid arthritis, traumatic osteoarthritis, ankylosing, spondylitis, hemophilic arthritis, peripheral vascular disease. 3. Cold urticaria. 4. Preoperative anticoagulation, patients had preoperative deep vein thrombosis (DVT). 5. Preoperative history of anemia
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rheumatoid Arthritis Patients who diagnosed of rheumatoid arthritis as of ACR/EULAR 2010 All patients age range is 18-80 years  Renal failure Hepatic insufficiency Diabetes mellitus Other collagen vascular diseases History of smoking and consumption of alcohol
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Urticaria Vitamin D Deficiency Adults >18 years of age, having urticaria episodes at least 2 days per week for 6 weeks or longer with/without angioedema  Patients with only physical urticaria, only dermatographism, urticarial vasculitis, hereditary or acquired angioedema Patients with BMI>25 kg/m2, dyslipidemia, diabetes, hypertension, pre-existing cardiovascular disease, cerebro-vascular accidents, hypothyroidism, smokers, and other systemic or cutaneous disorders including atopic dermatitis, psoriasis etc Patients with hypercalcemia (>11 mg/dL), diabetes, renal insufficiency, hepatic disorders, hyperparathyroidism, sarcoidosis, other granulomatous disorders, malignancy Pregnant and lactating women, patients who have taken Vit D supplementation in past 6 months